

MYLAN INC.  
Form 4  
February 27, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Mauro Anthony**

(Last) (First) (Middle)

1000 MYLAN BLVD

(Street)

CANONSBURG, PA 15317

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**MYLAN INC. [MYL]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**02/27/2015**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
☒ Officer (give title below) \_\_\_\_ Other (specify  
below) below)

President, North America

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired<br>(A) or Disposed of<br>(D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|---|---|--------------------------------------|--|--|--|---|
| Common<br>Stock <u>(1)</u> <u>(2)</u> | 02/27/2015                              |   | D                                    | 77,936   | D <u>(3)</u> 0   | D  |   |
| Common<br>Stock <u>(1)</u> <u>(2)</u> | 02/27/2015                              |   | D                                    | 5,574  | D <u>(3)</u> 0   | I  | By 401(k)<br>Plan   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

# Edgar Filing: MYLAN INC. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3)          | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|---|--|--------------------------------------|--|--------------------------------|---|--|---|
|   |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Employee Stock Option - Right to Buy <sup>(4)</sup> | \$ 22.66   | 02/27/2015                           |  | D                              | 4,757   | <sup>(5)</sup> 03/02/2021                                | Common Stock 4,757  |
| Employee Stock Option - Right to Buy <sup>(4)</sup> | \$ 23.44   | 02/27/2015                           |  | D                              | 4,266   | <sup>(6)</sup> 02/22/2022                                | Common Stock 4,266  |
| Employee Stock Option - Right to Buy <sup>(4)</sup> | \$ 30.9  | 02/27/2015                           |  | D                              | 3,236   | <sup>(7)</sup> 03/06/2023                                | Common Stock 3,236  |
| Employee Stock Option - Right to Buy <sup>(4)</sup> | \$ 55.84   | 02/27/2015                           |  | D                              | 12,009  | <sup>(8)</sup> 03/05/2024                                | Common Stock 12,009   |

## Reporting Owners

| Reporting Owner Name / Address                           | Relationships                    |
|--|----------------------------------|
|  | Director 10% Owner Officer Other |
| Mauro Anthony<br>1000 MYLAN BLVD<br>CANONSBURG, PA 15317 | President, North America         |

## Signatures

/s/ Bradley L. Wideman, by power of attorney  
02/27/2015

                    Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On February 27, 2015 (the "Closing Date"), Mylan N.V. completed the transaction (the "Transaction") by which it acquired Mylan Inc. and Abbott Laboratories' ("Abbott") non-U.S. developed markets specialty and branded generics business (the "Business"). Pursuant to the terms of the Amended and Restated Business Transfer Agreement and Plan of Merger, dated as of November 4, 2014, by and among Mylan Inc., New Moon B.V. (which has been renamed Mylan N.V. and is referred to herein as "Mylan"), Moon of PA Inc. ("Merger Sub"), and Abbott, on the Closing Date, Mylan acquired the Business and Merger Sub merged with and into Mylan Inc., with Mylan Inc. surviving as a wholly owned indirect subsidiary of Mylan and each share of Mylan Inc. common stock issued and outstanding was cancelled and automatically converted into and became the right to receive one Mylan ordinary share (the "Merger"). (Continued in Footnote 2)

(2) In connection with the Transaction, Mylan Inc. and the Business have been reorganized under Mylan, a new public company organized in the Netherlands. This report is being filed by the reporting person solely to report the disposition of shares of Mylan Inc. common stock in connection with the Transaction. The reporting person will file a separate Form 4 to reflect the corresponding acquisition of securities of Mylan in connection with the Transaction.

(3) Represents shares of Mylan Inc. common stock that were exchanged on a one-for-one basis for Mylan ordinary shares in connection with the Transaction. On the effective date of the Merger, the closing price of MYL was \$57.33 per share.

(4) Represents stock options of Mylan Inc. common stock that were exchanged for stock options of Mylan ordinary shares having substantially the same terms in connection with the Transaction.

(5) These options vested on March 2, 2014.

(6) These options vested on February 22, 2015.

(7) These options vest on March 6, 2016.

(8) These options vest in three equal annual installments beginning on March 5, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.